Form 4: Pfizer EVP Andrew Baum Granted 303,151 Stock Appreciation Rights

Pfizer Executive Vice President Andrew Baum received a grant of 303,151 Stock Appreciation Rights, which will settle in common stock on March 3, 2031.

Summary

• Andrew Baum, Executive Vice President of Pfizer Inc. (PFE), was granted 303,151 Stock Appreciation Rights (SARs).
• The SARs have a conversion or exercise price of $26.58.
• These rights are subject to certain vesting requirements.
• The SARs will be settled in shares of Pfizer common stock on March 3, 2031, which is the fifth anniversary of the grant date.
• The transaction date for this grant was March 3, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive incentive alignment and retention strategies, without directly impacting immediate financial performance.

Positives

• The grant of Stock Appreciation Rights aligns executive compensation with shareholder value creation, as the executive benefits from an increase in Pfizer's stock price.
• The long-term vesting and settlement period (5 years) encourages sustained performance and retention of key management.

Negatives

• Potential for future share dilution when the 303,151 SARs are settled in common stock, although this is a standard component of equity compensation plans.

Risks

• Dilution Risk: The settlement of SARs in common stock could lead to an increase in the number of outstanding shares, potentially diluting the ownership percentage of existing shareholders.
• Market Performance Risk: The value of the SARs to the executive is directly tied to Pfizer's stock performance; if the stock price does not appreciate significantly above the exercise price, the incentive value diminishes.

Future Outlook

The Stock Appreciation Rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on March 3, 2031. This indicates a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that the grant of Stock Appreciation Rights (SARs) is a common and widely accepted form of equity-based executive compensation within the pharmaceutical and broader corporate sectors. This mechanism is designed to align the interests of executives with those of shareholders by incentivizing an increase in the company's stock price, similar to stock options but often without the need for the executive to purchase shares.

Comparison to Industry Standards

• The use of Stock Appreciation Rights (SARs) as a long-term incentive is a standard practice across major pharmaceutical companies and large-cap corporations.
• Companies like Johnson & Johnson, Merck, and Eli Lilly frequently utilize similar equity-based compensation structures, including SARs or restricted stock units (RSUs), to retain and motivate key executives.
• The five-year vesting and settlement period for these SARs is consistent with typical long-term incentive plans designed to encourage sustained performance and executive retention.

Corporate Governance

Related Party Transactions

• Grant of 303,151 Stock Appreciation Rights to Andrew Baum, an Executive Vice President of Pfizer Inc., which constitutes a transaction between the company and a key management personnel.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon settlement of SARs, but also benefits from increased executive alignment with long-term stock performance.
• Executive (Andrew Baum): Receives a significant long-term incentive tied to the company's stock price appreciation, enhancing personal wealth potential.

Next Steps

• The Stock Appreciation Rights will vest over time according to specific requirements.
• The SARs will be settled in shares of Pfizer common stock on March 3, 2031.

Key Dates

Keywords

Pfizer, PFE, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, Form 4, Andrew Baum, Equity Grant